Fecal microbiota transplantation (FMT) for Clostridioides difficile infection (CDI) was largely safe and effective in a recent study of immunocompromised patients.
New research from the School of Medicine on fecal transplants benefiting patients with recurrent C. difficile infections
New research from the School of Medicine on fecal transplants benefiting patients with recurrent C. difficile infections.
Faecal microbiota transplantation (FMT) from healthy donors to patients with irritable bowel syndrome (IBS) has been attempted in two previous double-blind, placebo-controlled studies. While one of those studies found improvement of the IBS symptoms, the other found no effect. The present study was conducted to clarify these contradictory findings.
Faecal microbiota transplant as a medicinal product for the treatment of Clostridioides difficile infection
Faecal Microbiota Transplant (FMT) has improved outcomes for the treatment of Clostridioides difficile infection (CDI) compared to antibiotic therapy. In the largest UK cohort to date, we describe the clinical outcomes for 124 patients receiving FMT for recurrent or refractory CDI and present a framework to produce FMT as a…
The Potential of Microbiome Manipulation as a Therapeutic Strategy in Clostridium difficile Infection
Faecal microbiome transplantation (FMT) has generated huge recent interest, as it presents a potential solution to a significant clinical problem - the increasing incidence of Clostridium difficile infection. In the short term, however, there remain many practical questions regarding its use, including the optimal selection of donors, material preparation and…
Fecal Microbiota Transplantation (FMT) is a promising investigational treatment that involves transplanting carefully screened, processed stool from a healthy donor into a sick patient’s colon.
Faecal microbiota transplantation (FMT) with dietary therapy for acute severe ulcerative colitis